Étiquette : nausées

Bibliographie : Cannabinoïdes et CANCER, Docteur Christian SUEUR, GRECC, avril 2020.

Bibliographie Cannabinoïdes et CANCER   Docteur Christian SUEUR, GRECC, avril 2020.       1 - Activité anti-tumorale des cannabinoïdes : 2 - 14 2 - Cannabinoïdes et Soins Palliatifs dans les pathologies cancéreuses : 15 - 17 3 - Cannabinoïdes et santé mentale en cancérologie : 18 4 - Cannabinoïdes et douleurs cancéreuses : 19 - 23 5 - Cannabinoïdes et chimiothérapies (nausées et vomissements) : 24 - 25      

Lire la suite

Cannabinoids : the lows and the highs of chemotherapy-induced nausea and vomiting, Toni Leigh Mortimer et al., 2019

Cannabinoids : the lows and the highs of chemotherapy-induced nausea and vomiting Toni Leigh Mortimer, Tom Mabin & Anna-Mart Engelbrecht Future Oncology, 2019 Doi : 10.2217/fon-2018-0530   Despite remaining one of the most widely abused drugs worldwide, Cannabis sativa exhibits remarkable medicinal properties. The phytocannabinoids, cannabidiol and -9-tetrahydrocannabinol, reduce nausea and vomiting, particularly during chemotherapy. This is attributed to their ability to reduce the release of serotonin from enterochromaffin cells in the small intestine, which would otherwise orchestrate the vomiting reflex. Although there are many preclinical and clinical studies on the effects of -9- tetrahydrocannabinol during nausea and vomiting, little is known about the role [...]

Lire la suite

Bibliographie : Cannabinoïdes et Traitement des Nausées et Vomissements, Docteur Christian SUEUR, GRECC, 2e édition, janvier 2020

Bibliographie CANNABINOÏDES et Traitement des Nausées et Vomissements   Docteur Christian SUEUR, GRECC, 2e édition, janvier 2020.   Le Cannabis comme anti-émétique :   Les prescriptions médicales, chez les adultes (THC naturel ou synthétique - Nabilone) comme chez les enfants (delta 8-THC, Abrahamov et al, 1995), ont débutées dès 1975. L’efficacité a été prouvée dans de nombreux essais cliniques, et de nombreuses méta-analyses (8/9 pour le cannabis et 3/3 pour le Nabilone, Penta et al, 1981). Par contre les effets psychotropiques peuvent être mal supportés par de nombreux patients, et justifie l’arrêt, ou la diminution des doses. Les associations variables THC/CBD présente un intérêt probable. Aucun effet indésirable persistant ou fatal [...]

Lire la suite

Cannabis in Cancer Care, D.I. Abrams and M. Guzman, 2015

Cannabis in Cancer Care D.I. Abrams and M. Guzman Clinical Pharmacology & Therapeutics, 2015, 97, (6), 575-586. Doi : 10.1002/cpt.108   Cannabis has been used inmedicine for thousands of years prior to achieving its current illicit substance status. Cannabinoids, the active components of Cannabis sativa,mimic the effects of the endogenous cannabinoids (endocannabinoids), activating specific cannabinoid receptors, particularly CB1 found predominantly in the central nervous system and CB2 found predominantly in cells involved with immune function. Delta-9-tetrahydrocannabinol, themain bioactive cannabinoid in the plant, has been available as a prescriptionmedication approved for treatment of cancer chemotherapy-induced nausea and vomiting and anorexia associated with the AIDS wasting syndrome. Cannabinoidsmay [...]

Lire la suite

Regulation of nausea and vomiting by cannabinoids, Linda A Parker et al., 2011

Regulation of nausea and vomiting by cannabinoids Linda A Parker, Erin M Rock and Cheryl L Limebeer British Journal of Pharmacology, 2011, 163, 1411-1422. Doi : 10.1111/j.1476-5381.2010.01176.x   Abstract Considerable evidence demonstrates that manipulation of the endocannabinoid system regulates nausea and vomiting in humans and other animals. The anti-emetic effect of cannabinoids has been shown across a wide variety of animals that are capable of vomiting in response to a toxic challenge. CB1 agonism suppresses vomiting, which is reversed by CB1 antagonism, and CB1 inverse agonism promotes vomiting. Recently, evidence from animal experiments suggests that cannabinoids may be especially useful in treating the more difficult to control [...]

Lire la suite

The cannabinoids : An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection, R. Mechoulam & L. Hanus, 2001

The cannabinoids : An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection R. Mechoulam PhD, L Hanušs PhD Pain Research Management, 2001, 6, (2), 67-73. Doi : 10.1155/2001/183057   The present paper describes the historical use of cannabis, starting with its use in Assyria and China. Recent advances in the understanding of the molecular basis of cannabis action are explained, including the identification of the cannabinoid receptors CB1 and CB2, as well as the isolation of endogenous cannabinoids from the brain and periphery. The use of delta9-tetrahydrocannabinol as an antivomiting and antinausea drug for cancer [...]

Lire la suite

Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system, Keith A. Sharkey et al., 2014

Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system Keith A. Sharkey, Nissar A. Darmani, and Linda A. Parker European Journal of Pharmacology, 2014 January 5; 722. doi : 10.1016/j.ejphar.2013.09.068.   Abstract Nausea and vomiting (emesis) are important elements in defensive or protective responses that animals use to avoid ingestion or digestion of potentially harmful substances. However, these neurally-mediated responses are at times manifested as symptoms of disease and they are frequently observed as side-effects of a variety of medications, notably those used to treat cancer. Cannabis has long been known to limit or prevent nausea and vomiting from a variety of causes.This has [...]

Lire la suite

Priority Considerations for Medicinal Cannabis-Related Research, Marcel O. Bonn-Miller et al., 2019

Priority Considerations for Medicinal Cannabis-Related Research Marcel O. Bonn-Miller, Charles V. Pollack, Jr., David Casarett, Richard Dart, Mahmoud ElSohly, Larry Good, Manuel Guzman, Lumır Hanus, Kevin P. Hill, Marilyn A. Huestis, Eric Marsh, Susan Sisley, Nancy Skinner, Judith Spahr, Ryan Vandrey, Eugene Viscusi, Mark A. Ware, and Donald Abrams Cannabis and Cannabinoid Research, 2019, Volume 4, Number 3, 1-19. DOI: 10.1089/can.2019.0045   Keywords : medicinal cannabis; medical marijuana   Introduction and Rationale The National Academy of Sciences, Engineering, and Medicine’s 2017 publication The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research provided a significant contribution by synthesizing the existing evidence base [...]

Lire la suite

Cannabis For Cancer-Related Symptoms (CAFCARS), ClinicalTrials.gov Identifier : NCT03948074, mai 2019

Cannabis For Cancer-Related Symptoms (CAFCARS) https://clinicaltrials.gov/ct2/show/NCT03948074?recrs=abdf&cond=cannabis&draw=2&rank=98 ClinicalTrials.gov Identifier: NCT03948074 Recruitment Status : Not yet recruiting First Posted : May 13, 2019 Last Update Posted : May 13, 2019 See Contacts and Locations Sponsor: Pippa Hawley Information provided by (Responsible Party): Pippa Hawley, British Columbia Cancer Agency Study Description Brief Summary: Clinical evidence is urgently needed to be able to advise patients on which cannabis-based products to take, or to avoid, in managing cancer-related symptoms. This trial was therefore designed to determine which cannabis extract combination (High THC-Low CBD, Low THC-High CBD, or Equal amounts of THC and CBD) is most effective at treating cancer related symptoms for each [...]

Lire la suite